Table 1B.

Demographics by EGFR amplification status across all stage IV or recurrent esophagogastric cases in retrospective U of C cohort, excluding those prospectively screened between September 2014 and December 2016

CharacteristicEGFR amplifiedEGFR nonamplifiedP
Number of patients (%)10 (7)134 (93)< 2.2 × 10–16
Median age, y (range)64.5 (37–77)62 (22–83)0.83
Male sex, n (%)9 (90)93 (69)0.28
Disease site, n (%)
 Esophagus/GEJ6 (60)63 (47)0.52
 Gastric4 (40)71 (53)
Tumor grade, n (%)
 Well differentiated0 (0)4 (3)0.76
 Moderately differentiated1 (10)32 (24)
 Poorly differentiated8 (80)97 (72)
 Unknown1 (10)1 (1)
Stage at diagnosis, n (%)
 I0 (0)9 (7)0.94
 II0 (0)12 (9)
 III2 (20)30 (22)
 IV8 (80)83 (62)
 Unknown0 (0)0 (0)
HER2, n (%)
 Positive3 (30)30 (22)0.74
 Negative6 (60)83 (62)
 Equivocal0 (0)11 (8)
 Unknown1 (10)10 (11)
Race, n (%)
 Caucasian7 (70)104 (78)0.57
 African American2 (20)21 (16)
 Asian1 (10)9 (7)
 Hispanic0 (0)0 (0)